Therapeutic efficacy of FASN inhibition in preclinical models of HCC.

Haichuan WangYi ZhouHongwei XuXue WangYi ZhangRunze ShangMarie O'FarrellStephanie RoesslerCarsten StichtAndreas StahlMatthias EvertDiego F CalvisiYong ZengXin Chen

Published in: Hepatology (Baltimore, Md.) (2022)

This preclinical study suggests the limited efficacy of targeting FASN as monotherapy for HCC treatment. However, FASN inhibitors could be combined with other drugs for improved effectiveness. These combination therapies could be developed based on the driver oncogenes, supporting precision medicine approaches for HCC treatment.

Keyphrases

randomized controlled trial
combination therapy
systematic review
bone marrow
study protocol